SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

Mail Stop 6010

								August 4, 2005

Lee Hartwell
President and Chief Executive Officer
Hemosol Corp.
2585 Meadowpine Blvd.
Mississauga, Ontario L5N 8H9
Canada

	Re:	Hemosol Corp.
		Annual Report on Form 20-F for the Year Ended December
31,
2004
		Filed June 30, 2005
		File No. 0-50778

Dear Mr. Hartwell:

	We have reviewed your filing and have the following comments.
Where indicated, we think you should revise your document in
response
to these comments.  If you disagree, we will consider your
explanation
as to why our comment is inapplicable or a revision is
unnecessary.
Please be as detailed as necessary in your explanation.  In some
of
our comments, we may ask you to provide us with information so we
may
better understand your disclosure.  After reviewing this
information,
we may raise additional comments.

	Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We
look forward to working with you in these respects.  We welcome
any
questions you may have about our comments or any other aspect of
our
review.  Feel free to call us at the telephone numbers listed at
the
end of this letter.

FORM 20-F

Strategic Alliance with ProMetic, page 16

1. Based on the emphasis you place on the Cascade technology
throughout the filing, it appears you should file as exhibits the
license agreement and the strategic alliance agreement with
ProMetic.
See Instruction 4(b)(ii) to Exhibits in Form 20-F.  Please include
these exhibits in an amended Form 20-F.

Clinical Overview - Hemoloink, page 22

2. Please identify and describe the adverse events that caused you
to
halt clinical trials in March 2003.  Also, in the "Clinical
Highlights" discussion on page 23, identify and discuss the
principal
issues noted by Health Canada on April 25, 2001, by the U.K.
Medicines
Control Agency after your February 2001 submission, and by the FDA
on
August 13, 2001.

3. Please explain what you will need to do to re-initiate clinical
trials on Hemolink in the U.S., Canada, and the U.K.  For example,
will you need to re-submit any applications, or will you simply be
able to resume trials at will?

The Cascade Process, page 24

4. In this section, you state the Cascade technology extracts
certain
proteins from plasma.  We presume this means the plasma has less
of
the proteins after undergoing the Cascade technology.  However,
based
on the descriptions of the three target products on pages 26-27,
it
appears the Cascade technology will benefit people with
deficiencies
of those three products.  Please clarify how reducing the proteins
in
the plasma will cure a deficiency.  For example, is the plasma
that
goes through the Cascade from people other than the patient, as
opposed to a patient`s own plasma?

Share Ownership, page 56

5. Please disclose the percentage of total outstanding shares
owned by
each person in the table.  See Item 6.E of Form 20-F.

Item 15. Controls and Procedures, page 73

6. We note the CEO and CFO`s evaluation took place within 90 days
of
the date of filing, and the conclusion of effectiveness is "as of
the
date of his evaluation."  Item 15(a) of Form 20-F requires that
the
conclusion be as of the end of the period covered by the report,
not
as of a time within 90 days of filing.  Please revise this section
accordingly.

Consolidated Financial Statements

Auditors` Report, page F-2

7. Please tell us the name of the auditors.  Please note that the
auditors` opinion should include the name of the auditing firm as
required by Rule 2.02(a) of Regulation S-X.

Consolidated Statements of Loss, page F-4

8. It appears the future tax benefit recorded in Consolidated
Statement of Loss for 2004 is related to the net gain recorded on
the
sale of your future tax assets as disclosed in Footnote 9.  Please
tell us why you have recorded a benefit instead of a charge
related to
the future tax liability.  To assist us in understanding the
arrangement and the recording of the future tax liability, please
consider showing us the journal entries related to the sale of the
future tax assets.

*	*	*

	As appropriate, please amend your filing and respond to these
comments within 10 business days or tell us when you will provide
us
with a response.  You may wish to provide us with marked copies of
the
amendment to expedite our review.  Please furnish a cover letter
with
your amendment that keys your responses to our comments and
provides
any requested information.  Detailed cover letters greatly
facilitate
our review.  Please understand that we may have additional
comments
after reviewing your amendment and responses to our comments.

	We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filing to be certain that the
filing
includes all information required under the Securities Exchange
Act of
1934 and that they have provided all information investors require
for
an informed investment decision.  Since the company and its
management
are in possession of all facts relating to a company`s disclosure,
they are responsible for the accuracy and adequacy of the
disclosures
they have made.

	In connection with responding to our comments, please
provide, in
writing, a statement from the company acknowledging that:

* the company is responsible for the adequacy and accuracy of the
disclosure in the filing;

* staff comments or changes to disclosure in response to staff
comments do not foreclose the Commission from taking any action
with
respect to the filing; and

* the company may not assert staff comments as a defense in any
proceeding initiated by the Commission or any person under the
federal
securities laws of the United States.

	In addition, please be advised that the Division of
Enforcement
has access to all information you provide to the staff of the
Division
of Corporation Finance in our review of your filing or in response
to
our comments on your filing.

	You may contact Joseph Roesler at (202) 551-3628 or Mary Mast
at
(202) 551-3613 if you have questions regarding comments on the
financial statements and related matters.  Please contact Greg
Belliston at (202) 551-3861 or me at (202) 551-3715 with any other
questions.

								Sincerely,

								Jeffrey Riedler
								Assistant Director

cc:	Pardip Gill
	Director of Finance
	Hemosol Corp.
	2585 Meadowpine Blvd.
	Mississauga, Ontario L5N 8H9
	Canada
??

??

??

??

Lee Hartwell
Hemosol Corp.
August 4, 2005
Page 1

</TEXT>
</DOCUMENT>